Current pricing model for cancer drugs - is it 'Justum Pretium' for the developing world? Taking management of chronic lymphocytic leukaemia in India into consideration

Abraham M Varghese^{1

2}, Nitin Sood³, Sunitha M Daniel^{4

5}

Affiliations

¹ Department of Haematology, Little Flower Hospital and Research Centre, Angamaly, India.
² Department of Haematology, St James's University Hospital, Leeds, UK.
³ Department of Haematology, Medanta-The Medicity, Gurgaon, India.
⁴ Department of Palliative medicine, District General Hospital, Ernakulam, India.
⁵ Wolfson Palliative Care Research Centre, Hull York Medical School, University of Hull, Hull, UK.

Abraham M Varghese et al. Br J Haematol. 2020 Sep.

. 2020 Sep;190(5):e292-e294.

doi: 10.1111/bjh.16564. Epub 2020 Mar 9.

Abraham M Varghese^{1

2}, Nitin Sood³, Sunitha M Daniel^{4

5}

¹ Department of Haematology, Little Flower Hospital and Research Centre, Angamaly, India.
² Department of Haematology, St James's University Hospital, Leeds, UK.
³ Department of Haematology, Medanta-The Medicity, Gurgaon, India.
⁴ Department of Palliative medicine, District General Hospital, Ernakulam, India.
⁵ Wolfson Palliative Care Research Centre, Hull York Medical School, University of Hull, Hull, UK.

No abstract available

Keywords: chronic lymphocytic leukaemia; ibrutinib; pricing model.

References

1. Ahn, I.E., Basumallik, N., Tian, X., Soto, S. & Wiestner, A. (2019) Clinically indicated ibrutinib dose interruptions and reductions do not compromise long-term outcomes in CLL. Blood, 133, 2452-2455.
1. Akhtar, O.S., Attwood, K., Lund, I., Hare, R., Hernandez-Ilizaliturri, F.J. & Torka, P. (2019) Dose reductions in ibrutinib therapy are not associated with inferior outcomes in patients with chronic lymphocytic leukemia (CLL). Leukemia & Lymphoma, 60, 1650-1655.
1. Baviskar, J.B. (2016) Incidence of acute and chronic leukemias in rural area at tertiary care teaching hospital: a five years of study. Indian Journal of Pathology and Oncology, 3, 710.
1. Chen, Q., Jain, N., Ayer, T., Wierda, W.G., Flowers, C.R., O'Brien, S.M., Keating, M.J., Kantarjian, H.M. & Chhatwal, J. (2017) Economic Burden of Chronic Lymphocytic Leukemia in the Era of Oral Targeted Therapies in the United States. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 35, 166-174.
1. Chen, L.S., Bose, P., Cruz, N.D., Jiang, Y., Wu, Q., Thompson, P.A., Feng, S., Kroll, M.H., Qiao, W., Huang, X., Jain, N., Wierda, W.G., Keating, M.J. & Gandhi, V. (2018) A pilot study of lower doses of ibrutinib in patients with chronic lymphocytic leukemia. Blood, 132, 2249-2259.